secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jasper Therapeutics, Inc. (JSPR)
CIK:        0001788028
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001213900-23-012446
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Jasper Therapeutics reports positive briquilimab data: 3 SCD patients achieve 100% donor chimerism
--------------------------------------------------------------------------------

- First two sickle cell disease patients achieved 100% donor myeloid chimerism at Day 100; third at Day 30.
- All three patients increased hemoglobin at last follow-up (to 11.4–14 g/dL from baseline 8–10 g/dL).
- No graft-versus-host disease or briquilimab-related severe adverse events observed.
- Data presented in plenary session at 2023 Tandem Meetings (ASTCT/CIBMTR) on novel antibody-based conditioning.
- Study is Phase 1/2 (NCT05357482) evaluating briquilimab as conditioning for bone marrow transplant in SCD and beta thalassemia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/0001213900-23-012446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1788028/000121390023012446/ea173843-8k_jasper.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-012446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer